

Data Sharing in Clinical Trials

*Practical guidance on
anonymizing trial
datasets*



C Tuck, S Lewis, G Milne, C Keerie




THE UNIVERSITY of EDINBURGH

Today's talk

- Background to data sharing
- Current guidance
- Our work on anonymization
- How we use Datashare

Data sharing (1)



Data sharing (2)

- Usually at the end of the study
- Sharing data with unspecified secondary researchers
- Sharing data to the individual participant level

Anonymization (1)

- Anonymization and deidentification used interchangeably
- “information which does not relate to an identified or identifiable natural person or to personal data rendered anonymous in such a manner that the data subject is not or no longer identifiable” [Recital 26]
- Allows for wider use of information

Anonymization (2)


| Trial ID | Date of Enrolment | Initials | Age at Enrolment | Postcode | Gender |
|----------|---------------------|----------|------------------|----------|--------|
| A215 | | | 67 | EH1 | M |
| | | | 56 | OX4 | M |
| | | | 72 | IP2 | M |
| | Friday, 18 May 2012 | | 86 | SW1A | F |
| | | | 82 | KT6 | F |
| | | | 79 | EH4 | M |
| | | | 65 | IP3 | F |

The Daily

Queen enters clinical trial


Buckingham Palace announcement came as the Royal Family moved to quash rumours of Her Majesty's ill-health

The balancing act




MRC guidance (1)

- Aimed at CTUs
- Recommends a controlled access model
- Published April 2015



Good Practice Principles for Sharing Individual Participant Data from Publicly Funded Clinical Trials. Tudur Smith C, Hopkins C, Sydes M, Woolfall K, Clarke M, Murray G, Williamson P. April 2015.

MRC guidance (2)



The test case

- TOPPIC trial
- 240 participants

Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial



*Craig Mowat, Ian Arnott, Aiden Cahill, Malcolm Smith, Tariq Ahmad, Sreedhar Subramanian, Simon Travis, John Morris, John Hamlin, Anjan Dhar, Chuka Nwokolo, Cathryn Edwards, Tom Creed, Stuart Bloom, Mohamed Yousif, Linzi Thomas, Simon Campbell, Stephen J Lewis, Shaji Sebastian, Sandip Sen, Simon Lal, Chris Hawkey, Charles Murray, Fraser Cummings, Jason Goh, James O Lindsay, Naila Arebi, Lindsay Potts, Aileen J McKinley, John M Thomson, John A Todd, Mhairi Collie, Malcolm G Dunlop, Ashley Mowat, Daniel R Gaya, Jack Winter, Graham D Naismith, Holly Ennis, Catriona Keerie, Steff Lewis, Robin J Prescott, Nicholas A Kennedy, Jack Satsangi, for the TOPPIC Study Group**

Summary

Background Up to 60% of patients with Crohn's disease need intestinal resection within the first 10 years of diagnosis, and postoperative recurrence is common. We investigated whether mercaptopurine can prevent or delay postoperative clinical recurrence of Crohn's disease.


Methods We did a randomised, placebo-controlled, double-blind trial at 29 UK secondary and tertiary hospitals of patients (aged >16 years in Scotland or >18 years in England and Wales) who had a confirmed diagnosis of Crohn's

Lancet Gastroenterol Hepatol
2016; 1: 273–82

Published Online
August 30, 2016
[http://dx.doi.org/10.1016/S2468-1253\(16\)30078-4](http://dx.doi.org/10.1016/S2468-1253(16)30078-4)

Preparing the dataset

- What to remove?




- 28 participant identifiers (Hrynaszkiewicz & colleagues)
- Both direct and indirect identifiers to consider

Potential identifiers examples

| Direct Identifiers | Indirect Identifiers |
|---|--|
| Name | Place of treatment |
| Initials | Sex |
| Address, including full or partial postal code | Rare disease or treatment |
| Dates related to an individual (inc. date of birth) | Year of birth or age |
| Unique identifying numbers | Small denominators - population size of <100 |
| Medical device identifier | Very small numerators - event counts of <3 |


Preparing the dataset

- What to remove?



- 28 participant identifiers (Hrynaszkiewicz & colleagues)
- Both direct and indirect identifiers to consider
- Also – remove superfluous data (e.g audit)

Anonymisation process



Anonymisation process

1st pass

- Variables coded and assigned value
- Direct identifiers 01-14 (+15, superfluous)
- Indirect identifiers A-N
- 1st pass of data dictionary
 - Either direct/superfluous, indirect, or not requiring modification
 - Direct identifiers – assign method of anonymization
 - Indirect identifiers flagged

1st pass example

| Variable name | Description | Data type | Require anon (Y/N/?) | Reason code | Method |
|---------------|-----------------------|-----------|-------------------------|----------------|-----------|
| SubjectNo | Subject Number. | int | Y | 06 | Recode |
| AEDescription | description of the AE | int | ? | C, N | |
| Surgery | | int | ? | C | |
| StartDD | Start Date (day) | varchar | Y | 14 | Study day |
| StartMMM | Start Date (month) | varchar | Y | 14 | Study day |
| StartYYYY | Start Date (year) | varchar | Y | 14 | Study day |
| AECategory ID | | int | N | | |

Reason code 06 = Unique identifying number

Reason code 14 = Dates related to an individual

Reason code C = Rare disease or treatment

Reason code N = Verbatim responses or transcripts

Study day modification

- Use date of randomisation as day 0
- All other dates relative to date of randomisation
- e.g. date of randomisation 15/01/2014, start date of AE 16/01/2014
- New study date of AE = 1

Anonymisation process

2nd pass

- Indirect identifiers – decision to anonymise or leave alone
- Currently use a consensus model
- Some summarized to determine risk (event counts)
- May need medical input

2nd pass example

| Variable name | Description | Data type | Require anon (Y/N/?) | Reason code | Method |
|---------------|-----------------------|-----------|--------------------------------------|----------------|-----------|
| SubjectNo | Subject Number. | int | Y | 06 | Recode |
| AEDescription | description of the AE | int | ? Y on 2nd pass | C, N | |
| Surgery | | int | ? N on 2nd pass | C | |
| StartDD | Start Date (day) | varchar | Y | 14 | Study day |
| StartMMM | Start Date (month) | varchar | Y | 14 | Study day |
| StartYYYY | Start Date (year) | varchar | Y | 14 | Study day |
| AECategory ID | | int | N | | |

Reason code 06 = Unique identifying number

Reason code 14 = Dates related to an individual

Reason code C = Rare disease or treatment

Reason code N = Verbatim responses or transcripts

Dataset release

- Is it anonymous?
 - Motivated intruder test
 - May not be required for every dataset (risk based approach)
- Is it useful?
 - Re-run analysis with modified dataset
 - Further QC checking might be required

Summary on anonymization

- Generic rules can be created for direct identifiers
- Decisions on indirect identifiers on a trial-by-trial basis
- Balance anonymisation, data utility and practicality

Using Datashare

 DataShare

INFORMATION SERVICES

[Home](#) / [Edinburgh DataShare](#) / [College of Medicine & Veterinary Medicine](#) / [Edinburgh Medical School](#) / [Molecular, Genetic and Population Health Sciences](#)

Citation

Satsangi, Professor J. (2016). Toppic study, 2007-2015 [dataset]. University of Edinburgh. Edinburgh Clinical Trials Unit.

Description

Anonymised TOPPIC trial dataset


 Protocol No MRC G060329 Version 12 03 October 2013.pdf (1.167Mb)

 TOPPIC Anonymised data dictionary.pdf (305.6Kb)

 DATASET IN CSV FILES (566.7Kb)



 TOPPIC -Annotated CRFs.pdf (3.644Mb)

Application process



Questions?

- Thanks to:



Asthma UK Centre
for Applied Research

